Mirati Therapeutics

Home » Mirati Therapeutics

Secondary

Mirati Therapeutics

Mirati Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer.

Symbol

MRTX

Last Closing Price
$14.05

Shares
5,000,000

Effective Date
November 16, 2017

Underwriters
Cowen, Barclays

To view the prospectus for Mirati Therapeutics, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253